An observational study in Chronic Myelomonocytic Leukemia, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Centre Hospitalier Universitaire de Nice · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Leukemia, Myelomonocytic, Chronic with a site in France — 7 open to participants now, 11 under way, 1 of them phase 3. Leukemia, Myelomonocytic, Chronic · France.
Among the 46 studies in Leukemia, Myelomonocytic, Chronic with a site in France, this one is one of 2 that started in 2014, is one of 5 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 22nd registered.
540 studies on the registry are indexed under Leukemia, Myelomonocytic, Chronic; 69 are open to participants now.
Browse Leukemia, Myelomonocytic, Chronic studies →7 of the 46 studies in Leukemia, Myelomonocytic, Chronic with a site in France are open now. Recruiting first, the newest first:
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18–99
Cogent Biosciences, Inc. · Sites in France, United States, Australia and 11 more countries
Ages 18+
Taiho Oncology, Inc. · Sites in France, United States, Canada and 7 more countries
Ages 18+
Taiho Oncology, Inc. · Sites in France, United States, Armenia and 10 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 63 Leukemia, Myelomonocytic, Chronic studies recruiting now, 47 (75%) set no upper age limit and 7 (11%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 18 · Phase 3 11
First in 1993; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 152 across 38 observational studies indexed under Leukemia, Myelomonocytic, Chronic.
Median enrollment 86 across the 40 interventional studies, 60 across the 5 observational. Of the 31 that completed or were terminated, 11 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nice is the lead sponsor of 723 studies on the registry; 176 are open to participants now.
Centre Hospitalier Universitaire de Nice has 2 studies filed under Leukemia, Myelomonocytic, Chronic — fewer than ten, so there is no comparison to draw.
4 of the studies in Leukemia, Myelomonocytic, Chronic with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05552469Novartis PharmaceuticalsDose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases | 2027-02-01 |
| NCT03280888Centre Hospitalier Universitaire de NiceRelevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML) | 2027-11-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies in Leukemia, Myelomonocytic, Chronic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic Myelomonocytic Leukemia (CMML) is the most frequent of myelodysplastic/myeloproliferative syndromes, as defined by the WHO classification of myeloid malignancies. The median age at diagnosis is around 70 years with a strong male predominance. CMML is a clonal disease of the bone marrow hematopoietic stem cell mainly characterized by persistent monocytosis (>1x109/L) and the presence of immature dysplastic granulocytes in the peripheral blood of CMML patients. Allogeneic stem cell transplantation (ASCT) remains the only curative option in CMML. However, CMML patients are rarely eligible for this kind of therapy, mainly due to their advanced age. The gold standard treatment of CMML thus remains hydroxyurea, which is usually initiated when the disease becomes proliferative, and demethylating agents, which could be efficient in the most aggressive forms of CMML. Nevertheless, the pathogenesis of CMML remains poorly understood and new therapies are urgently needed for patients in treatment failure.
In recent years, a large numbers of gene mutations have been discovered in CMML, none of which are specific of this entity, as they can be encountered with different frequencies in other myeloid neoplasms. These mutated genes encode signaling molecules (NRAS, KRAS, CBL, JAK2, FLT3 and several members of the Notch pathway), epigenetic regulators (TET2, ASXL1, EZH2, IDH1, IDH2,.) and splicing factors (SF3B1, SRSF2, ZRSF2). Mutations in the transcription regulators RUNX1, NPM1 and TP53 have also been reported in CMML. However, the role of these mutations in leukemogenesis is still unclear. CMML is also characterized by defects in monocyte to macrophage differentiation. These defects in monocyte differentiation can be attributed to the presence of immature dysplastic granulocytes that secrete high levels of alpha-defensins HNP1-3 that antagonize the purinergic receptor P2RY6 in CMML patients. These CD14-/CD15+/CD24+ immature granulocytes that belong to the same clone than the leukemic monocytes seem to have immunosuppressive properties ressembling those of the myeloid-derived suppressor cells (MDCS) described in solid tumours. Whether these immature granulocytes contribute to autoimmune manifestations or immunoescape and progression of CMML is a conendrum and remains to be determined.
In this context, the proposed project aims at identifying news insights into the pathophysiology of CMML through a better definition of the phenotype and function of monocytes and immature granulocytes that characterize this pathology.
patients with chronic myelomonocytic leukemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Characterization of molecular mechanisms
Characterization of the molecular mechanisms involved in the lack of differentiation of monocytes originating from patients with CML.
Time frame: at 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2014 (actual). Primary completion is estimated for Nov 2027, 156 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Myelomonocytic, Chronic →
Centre Hospitalier Universitaire de Nice →